Deutsche Bank AG Has $136,000 Stock Holdings in Precigen, Inc. $PGEN

Deutsche Bank AG raised its holdings in Precigen, Inc. (NASDAQ:PGEN) by 35.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 91,031 shares of the biotechnology company’s stock after purchasing an additional 23,729 shares during the quarter. Deutsche Bank AG’s holdings in Precigen were worth $136,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of PGEN. Northern Trust Corp boosted its holdings in shares of Precigen by 11.6% in the 4th quarter. Northern Trust Corp now owns 1,168,689 shares of the biotechnology company’s stock valued at $1,309,000 after purchasing an additional 121,700 shares in the last quarter. Cary Street Partners Financial LLC acquired a new stake in shares of Precigen in the 4th quarter valued at $98,000. Stifel Financial Corp boosted its holdings in shares of Precigen by 182.2% in the 4th quarter. Stifel Financial Corp now owns 90,857 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 58,657 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Precigen in the 1st quarter valued at $87,000. Finally, Barclays PLC boosted its holdings in shares of Precigen by 28.3% in the 4th quarter. Barclays PLC now owns 242,899 shares of the biotechnology company’s stock valued at $272,000 after purchasing an additional 53,546 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PGEN shares. HC Wainwright reaffirmed a “buy” rating and issued a $8.50 target price on shares of Precigen in a report on Tuesday, August 19th. JPMorgan Chase & Co. upgraded Precigen from an “underweight” rating to a “neutral” rating in a research note on Friday, August 15th. JMP Securities increased their price target on Precigen from $6.00 to $8.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Precigen in a research note on Thursday, May 15th. Finally, Wall Street Zen upgraded Precigen from a “sell” rating to a “hold” rating in a research note on Saturday, July 12th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.25.

Precigen Stock Down 0.9%

Shares of NASDAQ:PGEN opened at $4.51 on Monday. The firm has a market cap of $1.34 billion, a P/E ratio of -10.74 and a beta of 1.81. Precigen, Inc. has a 12-month low of $0.65 and a 12-month high of $4.82. The business has a fifty day simple moving average of $2.16 and a 200 day simple moving average of $1.76.

Precigen (NASDAQ:PGEN) last announced its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. The business had revenue of $0.86 million during the quarter, compared to analyst estimates of $0.67 million. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%. As a group, equities research analysts expect that Precigen, Inc. will post -0.32 EPS for the current year.

Insider Transactions at Precigen

In related news, Director Nancy H. Agee bought 15,360 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was acquired at an average cost of $3.20 per share, with a total value of $49,152.00. Following the transaction, the director directly owned 192,196 shares in the company, valued at approximately $615,027.20. This trade represents a 8.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 47.10% of the stock is currently owned by corporate insiders.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.